B. Riley Securities initiated coverage of Radiance Medical with a rating of Buy and set a new price target of $15.00

RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate its First-In-Human (FIH) Phase 1 clinical trial of its Kallikrein Related Peptidase 3 (KLK3)-targeting radiotherapeutic, RAD 402, for t

Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to MRI Phase 2b clinical trial expected to complete enrollment and have topline data in 1H26 SYDNEY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the Phase 2b trial evaluating RAD101 imaging in brain metastases has achieved 50% patient enrollment threshold. "Enrolling 50% of the patients in our Phase 2b study of RAD101 is a meaningful achievement for

Data Safety Monitoring Committee approves advancing to a higher dose of 90mCi The first two Cohorts' patients show tumor uptake and a favourable safety profile SYDNEY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the completion of enrollment for the second cohort of patients in the Phase 1 dose escalation trial of 177Lu-RAD204 in PD-L1 positive advanced cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast ca

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held November 4th are now available for online viewing. VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. November 4th Company Presentations HUTCHMED (China) Limited(AIM: HCM, NASDAQ:HCM, and HKEX:13)First Pacific Company Ltd((HKEX: 142, OTC:FPAFY)Viomi Technology Co., Ltd(NASDAQ:VIOT)Epiroc AB((Nasdaq Stockholm: EPIA, OTC:EPO

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- In a release issued yesterday October 30, 2025 by Virtual Investor Conferences, please note several agenda items were modified. The corrected release follows: Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participating companies based in Australia, China, Hong Kong, Germany, Spain, Sweden, and the Cayman Islands will respond to questions during formal presentations. The conference is targeted to all categories

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participating companies based in Australia, China, Hong Kong, Netherlands, Denmark, Germany, Spain, Sweden, and the Cayman Islands will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pre

Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from solid tumors, confirming proof-of-concept with Phase 2 topline results expected by H1 2026First cohort of patients in Phase 1 clinical trial of RAD 202 (HER2) shows higher than expected tumour uptake; Anticipates second cohort of patients to be fully enrolled with data available by year-end 2025Data from first six patients in Phase 1 clinical trial of RAD 204 (PDL-1) show promising tumor uptake, stable disease at the first dose level in two out of three patientsData from Phase 1 study with RAD 301 supports decision to advance to Phase 2 imaging trial in patients with

RAD has received firm commitments for a A$35 million capital raising via an institutional private placement to new Australian and international institutional and sophisticated investors at A$0.03 per ordinary shareLantheus continues support as strategic investor with A$7.6 million investment in the placement, increasing its shareholding to 14.5%Share Purchase Plan for existing eligible shareholders in Australia and New Zealand to raise a further A$5 million (approx.) at A$0.03 per shareParticipants in the Placement and the Share Purchase Plan will receive one (1) free attaching option for every one (1) new share subscribed for under the offer, with an exercise price of A$0.039 and expiration

SYDNEY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 75mCi in the Phase 1 ‘HEAT' clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors. The DSMC is a multidisciplinary committee that conducts detailed reviews

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177 On track to complete enrollment of the first cohort of Phase 1 ‘HEAT' trial of RAD202 for treatment of advanced HER2-positive solid tumors U.S. FDA granted Fast Track Designation for RAD101 to distinguish between recurrent disease and the treatment effect of brain metastases Confirmed guidance of Cash Runway through to mid-2026 SYDNEY, Australia, July 29, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radi

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He w